INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here ...

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in ...

Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human ...

January 4, 2015. [File Courtesy, Standard] Eight new varieties of genetically modified (GM) cassava are ready for trials, according to the Kenya Plant Health Inspectorate Service.

Climate change is on track to reduce by 11 percent in 2100 the yields that today provide two-thirds of humanity's calories ...

The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based on data from clinical trials that showed 99.9% of participants who received it remained HIV negative.

Caris Life Sciences spikes by over 30% in IPO debut, embraces AI as future of oncology In an interview, the company’s president said cancer doctors need not be afraid of machine learning.

About This EventCaris Life Sciences (Nasdaq: CAI), a leading next-generation AI TechBio company and precision medicine pioneer, visits the Nasdaq MarketSite in Times Square.In honor of the ...

Caris Life Sciences Inc., a health care company that uses technology to help diagnose and treat cancer, raised $494 million in a U.S. initial public offering that priced above the top of its ...

Caris Life Sciences (CAI) stock is expected to make its trading debut on Wednesday after the company priced its IPO at $21/share. Read more here.

BOLD TYPES At BIO convention, Healey offers upbeat message to life sciences crowd By Jon Chesto Globe Staff,Updated June 18, 2025, 11:39 a.m.